Symmetric dimethylarginine concentrations in healthy neonatal foals and mares

Symmetric and asymmetric dimethylarginines in healthy and colic horses

This study investigated the plasma concentrations of symmetric dimethylarginine (SDMA) and asymmetric dimethylarginine (ADMA) in healthy horses and in horses affected by colic in relation to the type of colic and systemic inflammation response syndrome (SIRS) status. Upon admission (T0), horses underwent a physical examination, and the SIRS status was assessed. The horses with colic were divided retrospectively based on the type of colic, SIRS status, treatment, and outcome. SDMA and ADMA levels were measured at T0 and then every 24 h at four time points (T1, T2, T3, T4). Differences between groups (healthy, non-strangulating intestinal obstruction, strangulating intestinal obstruction, SIRS-positive, and SIRS-negative) were analysed with the Kruskal-Wallis test. Changes within groups over time were assessed using Friedman's two-way analysis of variance by ranks. Generalized linear mixed models (GLMMs) were used to analyze SDMA and ADMA levels in colic horses. Diagnostic accuracy was assessed using receiver operating characteristic curves, cut-off values, area under the curve analysis, and 95 % confidence intervals. SDMA concentrations were significantly lower in healthy horses compared to colic patients across all sampling times. ADMA levels were significantly higher at T2 in strangulating colic and SIRS-positive horses compared to healthy horses. GLMM analysis revealed no differences in SDMA or ADMA concentrations based on colic type, SIRS status, treatment, or outcome. Neither SDMA nor ADMA appeared to offer clinical utility as biomarkers in distinguishing between strangulating and non-strangulating colic or SIRS-positive and negative horses.

Validation of a reference interval for symmetric dimethylarginine in healthy goats and its comparison to values in goats with obstructive urolithiasis

BACKGROUND

Symmetric dimethylarginine (SDMA), a sensitive biomarker for detecting renal injury, has not been characterized in goats. Obstructive urolithiasis (OU) is the most common urinary tract disease in male small ruminants.

HYPOTHESIS/OBJECTIVE

Establish an SDMA reference interval (RI) in healthy adult goats and describe SDMA concentrations in goats with OU. We hypothesize that the SDMA RI in healthy adult goats will be similar to that of other adult veterinary species and that SDMA can be utilized to assess the renal function of goats experiencing OU.

ANIMALS

Fifty-five healthy adult male and female goats from a university herd were enrolled for SDMA RI development. Twenty male and female goats from a university herd were enrolled for validation of the SDMA RI established. Thirteen male goats diagnosed with OU were enrolled.

METHODS

Clinical trial. Serum samples for all animals enrolled were collected and analyzed for SDMA using an immunoassay (IDEXX Laboratories, Inc); goats with OU had additional blood work analyzed (PCV, total solids, and serum biochemistry). Symmetric dimethylarginine and other values in goats with OU were analyzed and compared at specific time points.

RESULTS

The SDMA RI for healthy, adult goats is 8.03 μg/dL (90% CI 4.81-11.04) to 25.93 μg/dL (90% CI 22.88-28.97). There was no correlation identified between serum creatinine and SDMA in goats with OU.

CONCLUSIONS AND CLINICAL IMPORTANCE

The SDMA RI for adult goats is higher than in other adult large animal species. Use of SDMA in goats with OU is not useful in assessing their renal function.

Biomarkers of Kidney Disease in Horses: A Review of the Current Literature

Creatinine only allows detection of kidney disease when 60 to 75% of the glomerular function is lost and is therefore not an ideal marker of disease. Additional biomarkers could be beneficial to assess kidney function and disease. The objectives are to describe new equine kidney biomarkers. This systematic review assesses the available literature, including the validation process and reference values, following which the authors suggest recommendations for clinical use. SDMA may have some potential as equine kidney biomarker, but there is currently a lack of evidence that SDMA offers any advantage compared to creatinine in detecting Acute Kidney Injury (AKI). Cystatin C and podocin show potential as biomarkers for kidney disease (including detecting AKI earlier than creatinine) and should be studied further. NGAL has potential as a biomarker of kidney disease (including detecting AKI earlier than creatinine), and potential as an inflammatory marker. Literature on MMP-9 does not allow for conclusive statements about its potential as a biomarker for kidney disease. The future may show that NAG has potential. For all biomarkers, at this stage, available scientific information is limited or too scarce to support clinical use, and only SDMA can be measured for clinical purposes. In conclusion, there are multiple new biomarkers with the potential to diagnose kidney problems. However, there are only a few studies available and more data is needed before these biomarkers can be applied and recommended in our daily practice.

Symmetric dimethylarginine concentrations in healthy neonatal foals and mares

BACKGROUND

Symmetric dimethylarginine (SDMA) is a renal biomarker correlated with glomerular filtration rate (GFR).

OBJECTIVES

Describe changes in SDMA in clinically healthy foals and their mares during the first month postfoaling.

ANIMALS

Convenience sampling of healthy periparturient Thoroughbred mares and their full-term foals from a population of client-owned horses.

METHODS

Serum and EDTA whole blood samples were collected from mares in their last month of pregnancy and then from mares and foals at approximately <12 hours, 48 hours, 7 days, and 30 days postbirth. Samples were processed at a commercial reference laboratory for CBC and serum biochemistry, including SDMA concentrations.

RESULTS

A total of 125 foals and 104 mares were included. Upper limits for SDMA concentrations in foals were above the adult horse reference interval for the first 20 or more days of life. Median SDMA concentrations decreased from 70 μg/dL (range, 7-100 μg/dL) to 18 μg/dL (range, 6-27 μg/dL) during the first 3 to 4 weeks of life. At birth, the SDMA concentration reference range was established as 0 to 100 μg/dL (upper limit of the assay); 0 to 85 μg/dL for 1 to 4 days old, 0 to 36 μg/dL for 5 to 10 days old, and 0 to 24 μg/dL for 20 to 30 days old. The upper reference limits for SDMA concentrations in mares did not differ from the general reference interval for adult horses. No correlation was identified between mare and foal SDMA concentrations (ρ = .06, P = .58).

CONCLUSIONS AND CLINICAL IMPORTANCE

Foal SDMA concentrations remained higher than the upper limit of the adult reference range and foals require a different reference range dependent on age.